Fri. Sep. 03, 2010  6:08pm CST
• Click to Login
• Free Trial
• Contact Us
• Zacks.com
Home My Portfolio Market Pulse Screening Focus List Timely Buys Growth and Income Zacks #1 Rank Help
Enter Symbol:

SYMBOL LOOKUP
  » Quote & Interactive Chart
  Interactive Java Chart
  Comparative Chart
  Company Profile
  Company News
  Detailed Research
  Quarterly Income Statement
  Annual Income Statement
  Quarterly Balance Sheet
  Annual Balance Sheet
  Annual Cash Flow Statement
  PDF Snapshot
  Earnings Calendar
  Zacks Equity Research


  » Quote & Interactive Chart for HAEMONETICS CORP
 
HAEMONETICS CORP
Exchange: NYSE
Symbol: HAE
Last Price
55.33
High Price
55.45
Low Price
54.64
Open Price
54.84
Net Change
0.77
Total Volume
125,955
Yield
0
Previous Close
54.56

All market data is at least 20 minutes delayed

52 Week High
60.70
52 Week Low
50.50
EPS Estimate (F1)
3.21
P/E Ratio
18.88
Avg. Broker Rec.
1.36
Zacks Rank
3
Zacks Recommendation
NEUTRAL

Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 06/15/2010
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis
Top Peers Ticker Zacks Rank
HAEMONETICS CORP HAE PREMIUM
CHEMBIO DIAGNOS CEMI PREMIUM
HILL-ROM HLDGS HRC PREMIUM
KENSEY NASH CP KNSY PREMIUM
See all MED PRODUCTS Peers
DETAILED RESEARCH
ZACKS COMMENTARY FOR HAE
Aug 25, 2010 Zacks Blog: Zacks Industry Outlook Highlights: Medtronic, Boston Scientific, St. Jude Medical, Haemonetics and Cyberonics
Aug 25, 2010 Zacks Analyst Interviews: Medical Devices Industry Outlook - August 2010
Aug 24, 2010 Zacks Blog: Medical Devices Industry Outlook - August 2010
Aug 24, 2010 Industry Outlook: Medical Devices Industry Outlook - August 2010
Aug 03, 2010 Zacks Blog: HAE Beats, Reaffirms 2010 Guidance
May 11, 2010 Zacks Blog: Zacks Industry Outlook Highlights: Medtronic, Inc., Haemonetics Corporation, Boston Scientific Corporation, St. Jude Medical Inc. and Becton, Dickinson and Company
May 10, 2010 Zacks Blog: Medical Devices Stock Review - May 2010
May 10, 2010 Industry Outlook: Medical Devices Stock Review - May 2010
May 05, 2010 Zacks Blog: Haemonetics Reports in Line
Apr 16, 2010 Zacks Blog: New Customer for Masimo

Performance information for other Zacks’ portfolios and strategies is available at: http://www.zacks.com/performance

 

Copyright ©2010 ZACKS Investment Research, Inc ("ZACKS"). All Rights Reserved. The information, data, analyses and opinions contained herein (1) includes confidential and proprietary information licensed from ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no guarantee of future performance. Investments in equities and other instruments are not guaranteed by any bank, are not insured by FDIC or any other agency, and involve investment risks, including possible loss of the principal involved.

One or more investment advisory accounts for which Zacks Investment Management acts as an investment advisor may own or have sold short securities and/or hold long and/or short positions in options reviewed in this publication, prior to the publication of such positions. Officers, directors and/or employees of Zacks Investment Management may own or have sold short securities and/or hold long and/or short positions in options reviewed in this publication.

Zacks Elite contains opinions, and none of the information contained therein constitutes a recommendation by Zacks Investment Research that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that the Zacks Elite will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. None of the information contained in the Zacks Elite may be deemed to be investment advice as such information is impersonal and not tailored to the investment needs of any specific person. PLEASE DO NOT EMAIL Zacks Elite, Zacks Investment Research, or a Zacks Elite Representative for PERSONALIZED INVESTMENT ADVICE, WHICH THEY CANNOT PROVIDE.

c_id: